大葉大學圖書館 |

Myeloid-derived suppressor cells and cancer[electronic resource] /

紀錄類型:	書目-語言資料,印刷品 : Monograph/item
杜威分類號:	616.079
書名/作者:	Myeloid-derived suppressor cells and cancer/ by David Escors ... [et al.].
其他作者:	Escors, David.
出版者:	Cham : : Springer International Publishing :, 2016.
面頁冊數:	ix, 102 p. : : ill., digital ;; 24 cm.
Contained By:	Springer eBooks
標題:	Suppressor cells.
標題:	T cells.
標題:	Cancer - Immunotherapy.
標題:	Biomedicine.
標題:	Immunology.
標題:	Cancer Research.
標題:	Oncology.
標題:	Cell Biology.
ISBN:	9783319268217
ISBN:	9783319268194
內容註:	Controversies in Neoplastic Myeloplasia -- Differentiation of Murine Myeloid-derived Suppressor Cells -- Human MDSCs -- Ex Vivo MDSC Differentiation Models -- Immunoregulatory myeloid cells in the tumor microenvironment -- Signal Transducer and Activation of Transcription 3: A Master Regulator of Myeloid-derived Suppressor Cells -- Future Perspectives.
摘要、提要註:	The book starts with an introduction to and history of myeloid-derived suppressor cells (MDSCs), followed by a description of their differentiation, their role in the tumour microenvironment and their therapeutic targeting. It closes with an outlook on future developments. In cancer patients, myelopoiesis is perturbed and instead of generating immunogenic myeloid cells (such as dendritic cells, inflammatory macrophages and granulocytes), there is an increase in highly immature MDSCs. These cells are distributed systemically, resulting in general immunosuppression. They also infiltrate tumours, promoting their progression and metastasis by inhibiting the natural anti-tumour immune response. As these cells also interact with classical anti-neoplastic treatments, they have become major therapeutic targets in the pharmaceutical industry and in oncology research.
電子資源:	http://dx.doi.org/10.1007/978-3-319-26821-7

Myeloid-derived suppressor cells and cancer[electronic resource] /
Myeloid-derived suppressor cells and cancer[electronic resource] /by David Escors ... [et al.]. - Cham :Springer International Publishing :2016. - ix, 102 p. :ill., digital ;24 cm. - SpringerBriefs in immunology,2194-2773. - SpringerBriefs in immunology..

Controversies in Neoplastic Myeloplasia -- Differentiation of Murine Myeloid-derived Suppressor Cells -- Human MDSCs -- Ex Vivo MDSC Differentiation Models -- Immunoregulatory myeloid cells in the tumor microenvironment -- Signal Transducer and Activation of Transcription 3: A Master Regulator of Myeloid-derived Suppressor Cells -- Future Perspectives.

The book starts with an introduction to and history of myeloid-derived suppressor cells (MDSCs), followed by a description of their differentiation, their role in the tumour microenvironment and their therapeutic targeting. It closes with an outlook on future developments. In cancer patients, myelopoiesis is perturbed and instead of generating immunogenic myeloid cells (such as dendritic cells, inflammatory macrophages and granulocytes), there is an increase in highly immature MDSCs. These cells are distributed systemically, resulting in general immunosuppression. They also infiltrate tumours, promoting their progression and metastasis by inhibiting the natural anti-tumour immune response. As these cells also interact with classical anti-neoplastic treatments, they have become major therapeutic targets in the pharmaceutical industry and in oncology research.

ISBN: 9783319268217

Standard No.: 10.1007/978-3-319-26821-7doiSubjects--Topical Terms:

639073
Suppressor cells.

LC Class. No.: QR185.8.S96

Dewey Class. No.: 616.079

Myeloid-derived suppressor cells and cancer[electronic resource] /
LDR:02226nam a2200325 a 4500 001 446433
003 DE-He213
005 20160908163704.0
006 m d
007 cr nn 008maaau
008 161201s2016 gw s 0 eng d
020 $a 9783319268217 $q (electronic bk.)
020 $a 9783319268194 $q (paper)
024 7 $a 10.1007/978-3-319-26821-7 $2 doi
035 $a 978-3-319-26821-7
040 $a GP $c GP
041 0 $a eng
050 4 $a QR185.8.S96
072 7 $a MJCM $2 bicssc
072 7 $a MED044000 $2 bisacsh
082 0 4 $a 616.079 $2 23
090 $a QR185.8.S96 $b M996 2016
245 0 0 $a Myeloid-derived suppressor cells and cancer $h [electronic resource] / $c by David Escors ... [et al.].
260 $a Cham : $b Springer International Publishing : $b Imprint: Springer, $c 2016.
300 $a ix, 102 p. : $b ill., digital ; $c 24 cm.
490 1 $a SpringerBriefs in immunology, $x 2194-2773
505 0 $a Controversies in Neoplastic Myeloplasia -- Differentiation of Murine Myeloid-derived Suppressor Cells -- Human MDSCs -- Ex Vivo MDSC Differentiation Models -- Immunoregulatory myeloid cells in the tumor microenvironment -- Signal Transducer and Activation of Transcription 3: A Master Regulator of Myeloid-derived Suppressor Cells -- Future Perspectives.
520 $a The book starts with an introduction to and history of myeloid-derived suppressor cells (MDSCs), followed by a description of their differentiation, their role in the tumour microenvironment and their therapeutic targeting. It closes with an outlook on future developments. In cancer patients, myelopoiesis is perturbed and instead of generating immunogenic myeloid cells (such as dendritic cells, inflammatory macrophages and granulocytes), there is an increase in highly immature MDSCs. These cells are distributed systemically, resulting in general immunosuppression. They also infiltrate tumours, promoting their progression and metastasis by inhibiting the natural anti-tumour immune response. As these cells also interact with classical anti-neoplastic treatments, they have become major therapeutic targets in the pharmaceutical industry and in oncology research.
650 0 $a Suppressor cells. $3 639073
650 0 $a T cells. $3 463587
650 0 $a Cancer $x Immunotherapy. $3 406740
650 1 4 $a Biomedicine. $3 463454
650 2 4 $a Immunology. $3 402223
650 2 4 $a Cancer Research. $3 463530
650 2 4 $a Oncology. $3 205017
650 2 4 $a Cell Biology. $3 463594
700 1 $a Escors, David. $3 468724
710 2 $a SpringerLink (Online service) $3 463450
773 0 $t Springer eBooks
830 0 $a SpringerBriefs in immunology. $3 605200
856 4 0 $u http://dx.doi.org/10.1007/978-3-319-26821-7
950 $a Biomedical and Life Sciences (Springer-11642)